Erratum to: The Autism Spectrum Disorders Stem Cell Resource at Children’s Hospital of Orange County: Implications for Disease Modeling and Drug Discovery: Stem Cells Translationalmedicine, 2014;3:1275–1286; http://dx.doi.org/10.5966/sctm.2014-0073;The autism spectrum disorders stem cell resource at children’s hospital of orange county: Implications for disease modeling and drug discovery

Stem Cells Translational Medicine

Volumn 3, Issue 11, 2014, Pages 1275-1287

  Brick, David J ^a   Nethercott, Hubert E ^a   Montesano, Samantha ^a   Banuelos, Maria G ^a   Stover, Alexander E ^a   Schutte, Soleil Sun ^b   O’dowd, Diane K ^b   Hagerman, Randi J ^c,d   Ono, Michele ^c,d   Hessl, David R ^c,d   Tassone, Flora ^c,d   Schwartz, Philip H ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autism spectrum disorder; Differentiation; Disease modeling; Induced pluripotent stem cells; Neural stem cell; Neuron

Indexed keywords

FLUORESCENT DYE; FRAGILE X MENTAL RETARDATION PROTEIN;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; AUTISM; AUTISM DIAGNOSTIC INTERVIEW REVISED; AUTISM DIAGNOSTIC OBSERVATION SCHEDULE; CELL DIFFERENTIATION; CHILD; CONTROLLED STUDY; CRYOPRESERVATION; DENSITOMETRY; FEMALE; FRAGILE X SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTELLIGENCE QUOTIENT; KARYOTYPING; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SOUTHERN BLOTTING; TEST RETEST RELIABILITY; WECHSLER INTELLIGENCE SCALE; ACTION POTENTIAL; ADOLESCENT; BIOLOGICAL MODEL; CELL LINE; CLINICAL TRIAL; GENETICS; HEALTH CARE FACILITY; METABOLISM; MULTICENTER STUDY; MULTIFACTORIAL INHERITANCE; NERVE CELL; NEURAL STEM CELL; PATHOLOGY; PLURIPOTENT STEM CELL; PRESCHOOL CHILD; STEM CELL;

ACTION POTENTIALS; ADOLESCENT; CELL DIFFERENTIATION; CELL LINE; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MODELS, BIOLOGICAL; MULTIFACTORIAL INHERITANCE; NEURAL STEM CELLS; NEURONS; STEM CELLS; TISSUE BANKS;

EID: 84908374745     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0073erratum     Document Type: Erratum

References (70)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.Arlington, VA: American Psychiatric Publishing, 2013.
2. Belmonte MK, Cook EH Jr., Anderson GM, et al. Autism as a disorder of neural information processing: Directions for research and targets for therapy. Mol Psychiatry 2004;9:646-663.
3. Grzadzinski R, Huerta M, Lord C. DSM-5 and autism spectrum disorders (ASDs): An opportunity for identifying ASD subtypes. Mol Autism 2013;4:12.
4. Atladottir HO, Gyllenberg D, Langridge A, et al. The increasing prevalence of reported diagnoses of childhood psychiatric disorders: A descriptive multinational comparison. Eur Child Adolesc Psychiatry 2014;.
5. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943;2:217-250.
6. Skafidas E, Testa R, Zantomio D, et al. Predicting the diagnosis of autism spectrum disorder using gene pathway analysis.MolPsychiatry 2012;19:504-510.
7. Lord C. Methods and measures of behavior in the diagnosis of autism and related disorders. Psychiatr Clin North Am 1991;14:69-80.
8. Hagerman R, Hoem G, Hagerman P. Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism 2010;1:12.
9. Luo R, Sanders SJ, Tian Y, et al. Genomewide transcriptome profiling reveals the functional impact of rare de novo and recurrent CNVs in autism spectrum disorders. Am J Hum Genet 2012;91:38-55.
10. Santini E, Huynh TN, MacAskill AF, et al. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 2013;493:411-415.
11. Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013;14:161-176.
12. Shelton JF, Hertz-Picciotto I, Pessah IN. Tipping the balance of autism risk: Potential mechanisms linking pesticides and autism. Environ Health Perspect 2012;120:944-951.
13. Hsiao EY, McBride SW, Chow J, et al. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc Natl Acad Sci USA 2012;109:12776-12781.
14. Pickett J, London E. The neuropathology of autism: A review. J Neuropathol Exp Neurol 2005;64:925-935.
15. Haroutunian V, Pickett J. Autism brain tissue banking. Brain Pathol 2007;17:412-421.
16. Schwartz PH, Bryant PJ, Fuja TJ, et al. Isolation and characterization of neural progenitor cells from post-mortem human cortex. J Neurosci Res 2003;74:838-851.
17. Schwartz PH, Tassone F, Greco CM, et al. Neural progenitor cells froman adult patientwith fragile X syndrome. BMC Med Genet 2005;6:2.
18. Park IH, Lerou PH, Zhao R, et al. Generation of human-induced pluripotent stem cells. Nat Protoc 2008;3:1180-1186.
19. Lewitzky M, Yamanaka S. Reprogramming somatic cells towards pluripotency by defined factors. Curr Opin Biotechnol 2007;18:467-473.
20. Saporta MA, Grskovic M, Dimos JT. Induced pluripotent stem cells in the study of neurological diseases. Stem Cell Res Ther 2011;2:37.
21. Peitz M, Jungverdorben J, Brüstle O. Disease-specific iPS cell models in neuroscience. Curr Mol Med 2013;13:832-841.
22. Bellin M, Marchetto MC, Gage FH, et al. Induced pluripotent stem cells: The new patient? Nat Rev Mol Cell Biol 2012;13:713-726.
23. Kondo T, Asai M, Tsukita K, et al. Modeling Alzheimer’s disease with iPSCs reveals stress phenotypes associated with intracellular Ab and differential drug responsiveness. Cell Stem Cell 2013;12:487-496.
24. Stover AE, Schwartz PH. Adaptation of human pluripotent stem cells to feeder-free conditions in chemically defined medium with enzymatic single-cell passaging. Methods Mol Biol 2011;767:137-146.
25. Stover AE, Brick DJ, Nethercott HE, et al. Process-based expansion and neural differentiation of human pluripotent stem cells for transplantation and disease modeling. J Neurosci Res 2013;91:1247-1262.
26. Filipovic-Sadic S, Sah S, Chen L, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 2010;56:399-408.
27. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 2000;30:205-223.
28. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-685.
29. Wechsler D. Wechsler Abbreviated Scale of Intelligence (WASI). San Antonio: Harcourt Assessment, Inc., 1999.
30. Hoffman LM, Carpenter MK. Characterization and culture of human embryonic stem cells. Nat Biotechnol 2005;23:699-708.
31. Maitra A, Arking DE, Shivapurkar N, et al. Genomic alterations in cultured human embryonic stem cells. Nat Genet 2005;37:1099-1103.
32. Nethercott HE, Brick DJ, Schwartz PH. Derivation of induced pluripotent stem cells by lentiviral transduction. Methods Mol Biol 2011;767:67-85.
33. Tassone F, Pan R, Amiri K, et al. A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. JMolDiagn 2008;10:43-49.
34. Tassone F, Longshore J, Zunich J, et al. Tissue-specificmethylationdifferences inafragile X premutation carrier. Clin Genet 1999;55: 346-351.
35. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000;66:6-15.
36. Nethercott HE, Brick DJ, Schwartz PH. Immunocytochemical analysis of human pluripotent stem cells. Methods Mol Biol 2011;767: 201-220.
37. Chan EM, Ratanasirintrawoot S, Park IH, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 2009; 27:1033-1037.
38. Kucharova K, Hefferan MP, Patel P, et al. Transplantation of rat synapsin-EGFP-labeled embryonic neurons into the intact and ischemic CA1 hippocampal region: distribution, phenotype, and axodendritic sprouting. Cell Transplant 2011;20:1163-1178.
39. Pruszak J, Sonntag KC, Aung MH, et al. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. STEM CELLS 2007;25:2257-2268.
40. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neurol 2014; 10:74-81.
41. Bourgeron T. A synaptic trek to autism. Curr Opin Neurobiol 2009;19:231-234.
42. Walsh CA, Morrow EM, Rubenstein JL. Autism and brain development. Cell 2008;135: 396-400.
43. Bagni C, Tassone F, Neri G, et al. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 2012;122:4314-4322.
44. Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008;113:427-438.
45. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol 2013; 12:786-798.
46. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotentstem cells from a spinal muscular atrophy patient. Nature 2009;457:277-280.
47. Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461:402-406.
48. Krey JF, Paşca SP, Shcheglovitov A, et al. Timothy syndrome is associated with activitydependent dendritic retraction in rodent and human neurons. Nat Neurosci 2013;16:201-209.
49. Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011;473:221-225.
50. Chung CY, Khurana V, Auluck PK, et al. Identification and rescue of a-synuclein toxicity in Parkinson patient-derived neurons. Science 2013;342:983-987.
51. Tervonen TA, Louhivuori V, Sun X, et al. Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiol Dis 2009;33:250-259.
52. Bhattacharyya A, McMillan E, Wallace K, et al. Normal neurogenesis but abnormal gene expression in human fragile X cortical progenitor cells. Stem Cells Dev 2008;17:107-117.
53. Comery TA, Harris JB, Willems PJ, et al. Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proc Natl Acad Sci USA 1997;94:5401-5404.
54. Cao Z, Hulsizer S, Cui Y, et al. Enhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expansion. J Biol Chem 2013;288:13831-13841.
55. Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002;125:1760-1771.
56. Greco CM, Berman RF, Martin R Metal.Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006;129:243-255.
57. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: Molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003;72:869-878.
58. Tassone F, Hagerman RJ, Garcia-Arocena D, et al. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J MedGenet 2004;41: e43.
59. Jacobs S, Doering LC. Astrocytes prevent abnormal neuronal development in the fragile X mouse. J Neurosci 2010;30:4508-4514.
60. Marchetto MC, Muotri AR, Mu Y, et al. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 2008;3:649-657.
61. Schwartz PH, Brick DJ, Stover AE., et al. Differentiation of neural lineage cells from human pluripotent stem cells. Methods 2008;45:142-158.
62. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011; 474:380-384.
63. Garbett K, Ebert PJ, Mitchell A, et al. Immunetranscriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008;30:303-311.
64. Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012;485:237-241.
65. Neale BM, Kou Y, Liu L, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012;485:242-245.
66. Helsmoortel C, Vulto-van Silfhout AT, Coe BP, et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet 2014;46:380-384.
67. Gao FB. Posttranscriptional control of neuronal development by microRNA networks. Trends Neurosci 2008;31:20-26.
68. Jin XF, Wu N, Wang L, et al. Circulating microRNAs: A novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell Mol Neurobiol 2013;33:601-613.
69. Rege SD, Geetha T, Pondugula SR, et al. Noncoding RNAs in neurodegenerative diseases. ISRN Neurol 2013;2013:375852.
70. Harris SL, Handleman JS. Age and IQ at intake as predictors of placement for young children with autism: A four-to six-year follow-up. J Autism Dev Disord 2000;30:137-142.